A
ACRC Studies | Poway, CA
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Baricitinib
LY3009104
Methotrexate
TAK-079
SEL-212
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
2 of 8 total trials
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...
Enrolling
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab
Trial sponsors
M
S
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems